An interventional study of Blood group determination and Antibody titration in COVID 19, sponsored by Hanane EL KENZ. Completed at 1 site in Belgium. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-20.
Sponsored by Hanane EL KENZ · Not applicable, Interventional, and Prevention
When the COVID-19 virus infects a person, it enters the lung epithelial cells of its host and uses its genetic material to replicate.
The pulmonary epithelial cells of a part of the population, known as "secretors", are capable of expressing the antigens of the "ABO" system on their surface. This secretory status can be established by determining the antigens of the Lewis blood group system. When the virus replicates in an "secreting" individual, the antigens of the "ABO" system of the infected individual will be present on the surface of the viruses formed in his/her lungs.
It was shown in 2003 that the response of a given individual to the transmission of a virus depends on his/her blood group and on the antigens of the "ABO" system carried by the virus. A patient of group "O" would thus defend himself much better against a virus carrying antigens of blood group "A", the natural antibodies "anti-A" of the patient reducing the ability of the virus to bind to its specific receptor on pulmonary epithelial cells, to penetrate them to replicate itself. The first data collected in Wuhan (China) seems to confirm this hypothesis. A COVID-19 virus transmission model can therefore be established on the basis of blood groups.
In order to reduce the spread of the virus among nursing staff, it is possible to establish a preferential algorithm for patient management based on the "ABO" and "Lewis" blood groups of patients and "ABO" of nursing staff in health care units, if operational and human conditions allow.
7,990 studies on the registry are indexed under COVID-19; 466 are open to participants now.
This study's enrollment of 566 is above the median of 102 across 4,364 interventional studies indexed under COVID-19.
Browse COVID-19 studies →Hanane EL KENZ is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Diagnostic Test: Blood group determination · Diagnostic Test: Antibody titration
Diagnostic Test: Blood group determination · Diagnostic Test: Antibody titration
Diagnostic Test: Blood group determination · Diagnostic Test: Antibody titration · Dietary Supplement: Probiotic
Determination of the blood group (ABO/LE)
Natural anti-A and anti-B antibody levels will be determined by a gel agglutination technique on the Biorad IH-500 automaton.
Administration of a probiotic to healthy volunteers to determine if it increases the level of circulating natural anti-A and anti-B antibodies (Probactiol Plus (Metagenics)).
Anti-A antibody concentration
Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.
Time frame: baseline
Anti-A antibody concentration
Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.
Time frame: Day 4
Anti-A antibody concentration
Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.
Time frame: Week 1
Anti-A antibody concentration
Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.
Time frame: Week 2
Anti-A antibody concentration
Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.
Time frame: Week 3
Anti-B antibody concentration
Anti-B antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.
Time frame: baseline
Anti-B antibody concentration
Anti-B antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.
Time frame: Day 4
Anti-B antibody concentration
Anti-B antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.
Time frame: Week 1
Anti-B antibody concentration
Anti-B antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.
Time frame: Week 2
Anti-B antibody concentration
Anti-B antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.
Time frame: Week 3
Blood group
Blood group (ABO/LE)
Time frame: baseline
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Probiotic
Hanane EL KENZ